The quoted risk of hemorrhage from dural arteriovenous fistulae with cortical venous reflux varies widely, and the influence of angiographic grade on clinical course has not previously been reported. OBJECTIVE: To assess the risk of hemorrhage and the influence of angiographic grade on this risk, compared with known predictors of hemorrhage such as presentation. METHODS: Seventy-five fistulae with cortical venous reflux identified in our arteriovenous malformations clinic between 1992 and 2007 were followed up clinically, and their angiograms were reviewed. RESULTS: There were 8 hemorrhages in 90 years of follow-up. The annual incidence of hemorrhage before any treatment was 13%, and 4.7% after partial treatment, giving an overall incidence of 8.9% before definitive treatment. Borden and Cognard grades were poor discriminators of risk for lesions with the exception of Cognard type IV lesions. These lesions, characterized by venous ectasia, had a 7-fold increase in the incidence of hemorrhage (3.5% no ectasia vs 27% with ectasia). Patients presenting with hemorrhage (20%) or nonhemorrhagic neurological deficit (22%) had a higher incidence of hemorrhage than those with a benign presentation (4.3%), but this may be directly linked to the presence of venous ectasia. CONCLUSION: In this series untreated dural arteriovenous fistulae with cortical venous reflux had a 13% annual incidence of hemorrhage after diagnosis. There was a significant difference between those with and without venous ectasia. This should be confirmed by further studies, but probably defines a high-risk subgroup of patients that requires rapid intervention.
W
hen and how to treat cranial dural arteriovenous fistulae (DAVF) depends on a thorough understanding of their natural history, because this needs to be compared with the risks of treatment. Unfortunately, most descriptions 1,2 and classifications 3,4 of these lesions are limited to their presentation, which is not directly relevant to clinical decisionmaking. In contrast, data on the natural history of DAVF are scarce and contradictory.
The first report on their behavior after presentation included a mixture of lesions, both with and without cortical venous reflux (CVR). 5 We now know that lesions without CVR are distinct and unlikely to follow an aggressive course, 6, 7 making it difficult to apply these early data to individual patients.
Until recently, only 2 reports of 20 patients with CVR were available. One studied a group of patients that had presented with an intracranial hemorrhage. 8 This found a very high rate of further hemorrhage-on average once in every 2 months of follow-up. The second landmark article followed a mixed group of patients with both hemorrhagic and nonhemorrhagic presentations and a significant number of patients who had been partially treated. This found a lower, but still high rate of hemorrhage, at 1 every 12 years. 9 Based on this, it was reasonable to recommend that all DAVF with CVR should be treated acutely and aggressively.
Two recent reports have cast doubt on this. Although they both emphasize the relevance of mode of presentation on future behavior, both found much lower rates of hemorrhage. In their cohorts, 1 hemorrhage occurred every 27 and 32 years. 10, 11 These data have cast doubt on the natural history of the disease and have questioned the risk of hemorrhage sufficiently to alter the decision if and when to treat some patients, and what mode of treatment to use in others.
We noted that previous studies included varying numbers of partially treated fistulae. The lesions studied also varied in their angiographic appearances and presentation. [8] [9] [10] [11] It has been shown that the mode of presentation predicts risk of future hemorrhage. 9, 10 Although the only report on partial treatment suggests that it does not influence risk, this assertion is based on 14 untreated and 6 partially treated lesions and is open to question. Most importantly the radiological Cognard and Borden classifications have never been applied to natural history, and it is thus unknown what relationship angiographic appearances have to the clinical course of these lesions. We therefore hypothesized that if these characteristics were predictive of hemorrhage risk, then this would explain the wide variations in the literature.
The aim of our study was therefore to establish the annual incidence of hemorrhage of DAVF with CVR, and to assess the relationship of partial treatment, angiographic grade, and presentation to this incidence. This would establish the main determinant of clinical course, which would allow accurate estimation of the risk posed by specific fistulae.
MATERIALS AND METHODS
Since 1992, the Wessex Neurological Centre has run a specific arteriovenous malformation clinic where all patients with DAVF have been prospectively recorded. In the 15 years up to 2007, 70 consecutive patients harboring 75 fistulae with CVR were seen and form the basis of this report.
All patients were treated aggressively with the aim of early eradication of CVR. This was not possible in some patients because of the poor clinical state at presentation, or because of technical problems obtaining complete eradication. All patients were discussed at a neurovascular multidisciplinary meeting by a neurosurgeon and a neuroradiologist. Although the heterogeneity of lesions and the evolution of techniques make standardization of treatment difficult, in general, if endovascular occlusion was deemed feasible, this was offered in the first instance.
Our embolization strategy has previously been described, 12 and is similar to other groups. 13 The aim of embolization is obliteration of the fistula and the venous recipient. For Cognard type 2 fistulae, this is usually achieved by a transvenous approach with primary obliteration of the sinus resulting in retrograde thrombosis of the fistula. Coiling the sinus is the established method of sinus occlusion. In cases of an isolated sinus, where percutaneous, transvenous access to the DAVF is not possible, transarterial embolization is the usual endovascular treatment option. In some cases, a combined approach may be necessary with a surgical burr hole, giving access for endovascular occlusion of the sinus. Transarterial liquid embolization is used for Cognard type 3 and 4 fistulae. Again, the aim is obliteration of the fistula and the venous recipient. In our center, Onyx has supplanted n-butyl-cyanoacrylate as the material of choice. The aim of surgery was to disconnect the CVR as described by other groups. 14 The clinical notes of all patients were retrospectively reviewed, classifying their presentation and clinical course as benign or aggressive. In addition to incidental and asymptomatic lesions, the benign group included those presenting with headaches, pulsatile tinnitus, or orbital phenomena. The aggressive group was subdivided into those with a nonhemorrhagic neurological deficit (NHND) or hemorrhage. All hemorrhages were confirmed on CT or MRI scans.
The follow-up period was divided into the untreated phase and, in patients who were partially treated, the partial treatment phase. Untreated times started at angiographic diagnosis and ended on the date of treatment, last follow-up, or death. Partial treatment times started on the date of incomplete treatment and ended at definitive treatment, last follow-up, or death. All deaths were investigated. All death certificates were obtained and, where available, post mortem reports.
A consultant neurosurgeon and a consultant neuroradiologist assessed all angiograms. CVR was confirmed, and each fistula was classified on the Borden and Cognard scales (Table 1) . 3, 4 Lesions were also assessed for the presence of venous ectasia. These lesions are the same as Cognard IV lesions, which are defined as fistulae with a venous dilatation more than 5 mm and 3 times the diameter of the draining vein.
Age at presentation was compared by the use of a 2-tailed unpaired Student's t test. Presentation with hemorrhage and the presence of venous ectasia were compared by the use of the Fisher exact test. Hemorrhage incidence rate after diagnosis was calculated per patient year and expressed as a percentage. Groups were compared with incidence rate differences (IRDs) and ratios (IRRs), and their 95% confidence intervals calculated by the test-based method. P values were calculated by the use of a separate model where cumulative event-free survival was compared by using Kaplan-Meier analysis with log-rank testing.
RESULTS
Forty-seven patients were male (67%) and 23 were female (33%). The mean age at diagnosis was 61 years (range, 32-86). The location of the fistulae is illustrated in Table 2 .
In total the 75 fistulae had 90 years of follow-up. Seventy-one fistulae were followed up until definitive treatment; 1 untreated patient died, 2 partially treated patients remain under review, and 1 partially treated patient has been lost to follow-up. The length of follow-up ranged from 1 day to 13 years. During this period, 8 patients experienced a further hemorrhage. The crude annual hemorrhage rate was 8.9% (confidence interval [CI], 5.7%-12%). Three further patients experienced an aggressive course secondary to venous hypertension or infarction. The total event rate was 12% (CI, 8.5%-16%). One patient with progressive cognitive decline died. The annual death rate was 1.1% (CI, 0%-2.2%).
Twenty-eight of the 75 fistulae had a period of partial treatment. There were 47 years of follow-up of untreated fistulae and 43 years of follow-up of partially treated fistulae. There was no difference in age at presentation (P = 0.72), mode of presentation (P = 1.00), or presence of venous ectasia (P = 0.51) between these groups. Partial treatment consisted of failed surgical disconnection of CVR in 5 cases, failed sinus occlusion with coils in 3 cases, and partial obliteration from the arterial side in 20 cases. Onyx was used in 11, polyvinyl alcohol in 5, n-butyl-cyanoacrylate in 2, and tungsten in 1 case. The embolic agent was not recorded in the remaining case. Full details of the management strategy and outcomes have been published previously. 12 There were 6 bleeds and 2 NHNDs in the untreated phase with an annual hemorrhage rate of 13% (CI, 7.5%-18%) and an event rate of 17% (CI, 11%-23%), and 2 bleeds and 1 NHND in the partially treated phase with an annual hemorrhage rate of 4.7% (CI, 1.7%-8.0%) and an event rate of 7.0% (CI, 3.0%-11%). The IRD for hemorrhage was 28.0% (CI, 220% to 4.3%), and the IRR was 0.37 (CI, 0.08-1.7). In the Kaplan-Meier model this did not reach statistical significance on log rank (P = 0.11). The hemorrhage rate in the untreated group appeared constant; however, it was notable that there were no hemorrhages in the first 2 years of follow-up of the partially treated group, which appeared to follow a more complex relationship with time ( Figure 1 ). In view of the potentially different behavior of partially treated lesions, only the untreated periods were considered for further analysis.
The rates of hemorrhage were analyzed based on the Borden classification. Nineteen Borden 2 fistulae with 14 years of untreated follow-up had one hemorrhage with an annual hemorrhage rate of 7.3% (CI, 0%-15%). Fifty-six Borden 3 fistulae with 34 years of untreated follow-up had 5 hemorrhages with an annual hemorrhage rate of 15% (CI, 8.2%-22%).
The same fistulae were then analyzed using the Cognard classification. Nine Cognard IIb fistulae with 11 years of untreated follow-up had one hemorrhage with an annual hemorrhage rate of 9.0% (CI, 0%-18%). Ten Cognard IIa1b fistulae suffered no hemorrhages in 2.6 years of untreated follow-up. Twenty-five Cognard III fistulae had no hemorrhages in 15 years of untreated follow-up. Thirty-one Cognard IV fistulae with 19 years of untreated follow-up had 5 hemorrhages with an annual hemorrhage rate of 27% (CI, 15%-38%). Of these 31 Cognard IV fistulae, 7 presented with benign symptoms, 9 with NHNDs, and 15 with a hemorrhage.
By definition, Cognard IV fistulae have venous ectasia and Cognard IIb, IIa1b, and III do not. We therefore analyzed the 44 fistulae without venous ectasia as a single group. These were followed up for 28.5 years and experienced 1 hemorrhage. The annual hemorrhage rate was 3.5% (CI, 0%-7.0%). The IRD between fistulae with and without venous ectasia was 23% (CI, 2.3%-44%), and the IRR was 7.6 (CI, 1.2-47). The groups were also significantly different on log rank testing (P = 0.03; Figure 2 ).
Thirty-two fistulae presented with a hemorrhage. Four experienced a further hemorrhage during 20 years of untreated followup. The annual hemorrhage rate was 20% (CI, 10%-31%). Nineteen fistulae presented with a NHND. One experienced a hemorrhage during 4.5 years of untreated follow-up. The annual hemorrhage rate was 22% (CI, 0%-44%). Twenty-four fistulae had a benign presentation. One had a hemorrhage during 23 years of untreated follow-up. The annual hemorrhage rate was 4.3% (CI, 0%-8.7%). There was no statistical difference between hemorrhagic and nonhemorrhagic presentation (IRD = 9.5%; CI, 213 to 32%; IRR = 1.9; CI, 0.43-8.2; log rank P = 0.38) or between aggressive and benign presentation (IRD = 16%; CI, 23.9 to 37; IRR = 4.8; CI, 0.69-33; log rank P = 0.14), although the size of the subgroups was small (Figures 3 and 4) .
DISCUSSION
In this series of 75 DAVF with CVR, the annual incidence of hemorrhage before any treatment was 13%, and 4.7% after partial treatment, giving an overall annual incidence of 8.9% before definitive treatment. Because the assumption that partially treated lesions behave the same as untreated lesions is uncertain, we performed all further analysis with the use of untreated lesions only, and report an untreated hemorrhage incidence of 13%, which we believe is the most relevant to clinical decision making.
Effect of Partial Treatment
We attempted to isolate differences between series that would explain the wide variations in the reported hemorrhage rates. One difference was that some series included fistulae that had been partially treated without complete obliteration of CVR. This has been accepted practice based solely on a series of 14 untreated and 6 partially treated fistulae.
9 These small numbers leave this assertion open to question.
In our series, the hemorrhage rate in untreated fistulae was 13% and in partially treated fistulae, 4.7%. The difference approached but did not reach significance on a survival analysis. However, because of the rarity of this pathology, a statistical difference could easily have been missed.
It was also noted that there were no hemorrhages in the first 2 years after partial treatment. It is therefore also possible that, whereas untreated fistulae appear to have a fairly constant risk of hemorrhage, partially treated fistulae may not, and that partial treatment provides a degree of short-term protection. In our series, most partial treatment comprised partial embolization of the fistula and arterial feeders. In such cases it might be expected that venous pressure and hence bleeding risk are transiently reduced, before recruitment of new arterial feeders with the restoration of pathological venous pressure.
Our series is similar in size to van Dijk et al in terms of years of patient follow-up. However, it achieves this similarity with relatively more patients followed up for shorter periods of time. Thus, our series is more sensitive to any short-term effect of partial treatment, and this may explain why they observed such poor FIGURE 1. Kaplan-Meier plots of the hemorrhage-free survival of untreated and partially treated fistulae. A, in the first 2 years following partial treatment there were no hemorrhages. B, overall there was no significant difference between groups on log rank ( P = 0.11). outcomes after the longer-term follow-up of partial treatment (4 died, 1 severe disability, and 1 moderate disability). In any event, we would not want to suggest that partial treatment is clinically useful, but rather point out the heterogeneity of this subgroup and its potential consequences for epidemiological studies. Therefore, we only considered the untreated group for all further analysis.
Angiographic Grade
Both the Borden and Cognard classifications are based on angiographic appearances. They were conceived and validated for the presentation of DAVF. 15 The number of fistulae detected and their presentation will vary with local scanning policy and referral patterns, and will not necessarily reflect the underlying nature of the pathology. It is the natural history with which intervention must be compared, and therefore is the only data of clinical relevance. Despite this, the natural history of these groups has not previously been specifically examined.
The hemorrhage rates in Cognard IIb, IIa1b, and III were low. Type IV lesions characterized by venous ectasia carry a more than 7 times higher rate of future hemorrhage. Therefore, although we found that Borden 3 fistulae had double the hemorrhage rate of Borden 2 lesions, when lesions with venous ectasia were excluded, there was no difference between Borden 2 and Borden 3 fistulae. Thus, in our series, the Borden and Cognard classifications did not discriminate different hemorrhage incidence rates, and the only radiological feature that was associated with a different hemorrhage rate was the presence of venous ectasia.
Mode of Presentation
Fistulae presenting with either hemorrhage or NHND had a high rate of further hemorrhage (20% and 22%) compared with those with a benign presentation (4.3%). This difference did not reach statistical significance. This is in contrast to 2 studies that found presentation with hemorrhage, 10 and presentation with aggressive symptoms, 11 had a statistically higher chance of future hemorrhage. All 3 studies are similar and only just large enough to be able to show such a difference. It may therefore be that we missed a significant difference by random chance.
We considered whether we could identify an extremely highrisk group by considering only those fistulae with a venous ectasia that had bled. Surprisingly, we found a very similar rate of hemorrhage in this group. Although the number of patients is small, a Kaplan-Meier plot of the patients with venous ectasia suggests no difference between those presenting with or without a hemorrhage. Thus, if presentation does have an effect on hemorrhage rate as in previous studies, this may not be an independent effect, and the true risk of the lesion may be determined by the presence of venous ectasia.
Classification
In this series, both the Cognard and the Borden classifications had shortcomings in predicting the future behavior of DAVF. The Cognard system includes redundant groups, which make its clinical utilization difficult, and the Borden system does not directly differentiate risk groups. A newer classification combining clinical presentation with radiological findings has also been proposed. 16 However, before its widespread adoption, more data will be required to establish whether hemorrhagic presentation and venous ectasia on angiography are independent risk factors. Based on our results, the only significant predictor of future hemorrhage was the presence of venous ectasia and hence perhaps a simpler classification of DAVF would simply be-no CVR, CVR without venous ectasia, and CVR with venous ectasia.
Differences Between Previous Studies
A synopsis of the results of the previous studies reporting on the natural history of DAVF with CVR is illustrated in Table 3 . Duffau et al 8 only considered lesions that had presented with hemorrhage and included a high proportion of lesions with venous ectasia. This may in part explain their very high rates of hemorrhage. Van Dijk et al 9 found a very similar rate of hemorrhage. If anything, inclusion of partially treated and no Cognard IV lesions may lead to an underestimate of risk. Soderman et al 10 did not report Cognard grade, and it is possible that any differences in hemorrhage rates are due to different incidences of venous ectasia in the respective series. At first glance the annual risk reported by Strom et al 11 is only one quarter that of our series. This could be explained by the inclusion of a large number of partially treated lesions. However, they also included only 2 type IV fistulae. Thus, their hemorrhage rate of 3.1% is very much in keeping with the hemorrhage rate in our fistulae without a venous ectasia (3.5%). Therefore, differences in the anatomy, presentation, and treatment of lesions in the previously reported studies are likely to explain the wide range in quoted hemorrhage rates.
Study Limitations
Although unique in being a prospectively identified consecutive series of fistulae, there was no strict prospective management or follow-up protocol in this study. Thus, the management of these patients will have varied. This is unfortunate, but the understanding of the natural history and management of these lesions is constantly evolving, and it would have been difficult to set such protocols in 1992 when the Cognard and Borden classifications had not yet been described. However, all DAVF in Wessex were managed by a single surgeon during the study period. This should have helped standardize the diagnosis, management, and followup of these patients.
The number and type of DAVF diagnosed may have varied with the availability of CT and MRI in the region, and the rate of angiographic investigation by the neurosciences unit. The threshold for performing CT and MRI scans has reduced over time, and, thus, we would expect an increasing proportion of lesions to be benign. In view that this series is more recent than most previous reports, yet had a higher hemorrhage risk, this is unlikely to have been a significant factor. Furthermore, we have for a long time had a low threshold for performing angiography including external carotid injections to look for DAVF, because we believe that there has been a relative underdiagnosis of the condition owing to a failure to look for it, which has only recently been recognized. This low threshold for angiography, as for CT and MRI, would be expected to reduce risk.
The ideal management protocol for a study of the natural history of DAVF would be conservative treatment for all patients. Clearly, this would not be ethical, and it is unlikely that such data will ever be produced. The best alternative is to have a standardized treatment protocol. Our policy was to treat all DAVF with CVR early. This was not achieved in a number of patients because of the difficulty treating the lesion or poor clinical state of the patient. It is possible that this led to delay of treatment of more benign lesions and earlier treatment of aggressive lesions. Once again, this would be expected to lead us to underestimate risk and is thus unlikely to have been a significant problem, because we found a higher rate of hemorrhage than most studies.
Because the patients with prolonged follow-up all had reasons why treatment could not be performed, we did not subject them to the risks of follow-up angiography unless there was a change in symptoms that could represent a change in the fistula. Thus, most of our follow-up was clinical. This has implications for the time at risk of these lesions. We used the simplest and most widely applied The current study is included in the last row. We have quoted our overall hemorrhage risk (of both untreated and partially treated lesions) for comparison with previous studies, although the untreated risk of 13% may be more clinically relevant. c Annual risk is defined as the number of hemorrhages per year of patient follow up expressed as a percentage. This is in keeping with previous studies. 9-11 652% was derived from the data published by Duffau et al. 8 It must be interpreted cautiously as it does not strictly mean the risk of a given patient having a haemorrhage in a year which could not exceed 100%.
interpretation at the time of risk. 9 This is defined from the time of first angiogram until treatment or last follow-up. We appreciate that there are merits in breaking down periods of follow-up because they have different weights of evidence. 17 However, with the amount of data available, this generates small subgroups, which are difficult to interpret. 18 This may have led to the inclusion of some spontaneously resolved fistulae in the analysis. Theoretically, this would lead us to underestimate the risk of hemorrhage.
We have also tried to identify factors predicting an aggressive or benign course. This should have identified any preponderance of high-or low-risk lesions due to selection bias, which we did not find. Differences in study populations, however, appear to explain some of the differences between reported series. To clarify these issues, further subanalysis will be needed, which will require a large number of patients. Because of their low incidence, this is beyond the remit of any single-institution series, and in view of their aggressive course, it will probably not be ethical to collect such data in the future. It will therefore require cooperation between units or a pooled analysis of existing data if these questions are to ever be definitively answered.
Clinical Implications
The high rates of hemorrhage seen in this series refute the recent contention that DAVF with CVR have a lower risk than thought. Clinically, this means that it is essential to treat these lesions early. It also suggests that it may be unwise to use modalities with a delayed action such as radiosurgery. It is true that some of the subgroups that we have described carry a lower risk, and it is possible they could be managed differently. However, in our experience, endovascular and microneurosurgical techniques have yielded excellent results with low morbidity, 12 and certainly do not carry an additional 13% procedural risk that would be required to justify radiosurgery if it were equally effective at 1 year. It will therefore be hard to justify an alternative approach in any except the most problematic of cases.
CONCLUSION
In this series, untreated DAVF with CVR had a 13% (CI, 7.5%-18%) annual rate of hemorrhage after diagnosis. The absence of venous ectasia was associated with a 3.5% (CI, 0%-7.0%) hemorrhage rate. Conversely, the presence of venous ectasia was associated with an annual hemorrhage rate of 27% (CI, 15%-38%). This observation should be confirmed by further studies, but probably defines a highrisk subgroup of patients that requires rapid intervention.
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W
ith this interesting and well-written article the team at Wessex Neurological Centre has elucidated the impact of venous ectasia on the natural course of DAVF. In their material the annual incidence of hemorrhage from a DAVF with venous ectasia was 27% (confidence interval [CI], 15-38%), regardless of presentation. This is an important observation that in addition coincides with the previously known relations between venous disposition and presentation with hemorrhage.
1 Their findings are thus quite probable but should nevertheless be validated in an independent material.
If the annual risk for hemorrhage from these lesions with venous ectasias is indeed as high as 27%, management strategies should take that into account. On the other hand, in this material the absence of venous ectasias was associated with a hemorrhage rate of 3.5% (CI, 0-7.0%), and thus these lesions may be quite benign.
In our service patients with DAVF with cortical venous reflux are most often offered endovascular treatment as the first option. However, surgical disconnection is not infrequent. In some cases, when endovascular treatment or surgery is not an option, the patients are offered Gamma Knife radiosurgery and the results are excellent. 2, 3 However, it should be noted that the risk for hemorrhage after radiosurgery is proportional to the natural course, and thus a favorable natural course would also improve the results of radiosurgery.
Data are contradictory and confusing. Thus it seems wise not to be too dogmatic concerning the risk of hemorrhage from a DAVF. All the present studies are very small, all have their biases and limitations and it seems the studied populations may differ significantly. As pointed out in the article it would be interesting if we could pool the materials from several centers and thus increase study power. We need to have more data.
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